Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participants may register here. The live ...

European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, ...

The new application was based on results from the Phase III SCOUT-HCM trial.

Learn which common medications you need to avoid when you have oHCM, including some for blood pressure and erectile ...

The human heart is a muscle, but it’s also a kind of complicated balloon—a balloon that fills and empties roughly 60 to 100 times every minute, and several billion times during the course of a ...

Hypertrophic cardiomyopathy (HCM) is a condition that thickens some of the heart’s muscles, making it harder for the heart to pump blood. Hypertrophic cardiomyopathy (HCM) usually affects the ...

What is Hypertrophic Cardiomyopathy (HCM)? Hypertrophic cardiomyopathy (HCM) is a condition that affects the muscle layer of the heart in patients without any underlying heart problems or systemic ...

US FDA accepts for priority review Bristol Myers Squibb’s sNDA for Camzyos to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy: Princeton, New Jersey T ...

From next-generation medications to groundbreaking gene therapies and nonsurgical procedures, explore the pipeline of treatments currently being tested for oHCM.

Hypertrophic cardiomyopathy is a genetic heart condition where the heart muscles become thickened and stiff, making it difficult for the heart to pump blood around the body effectively. Usually the ...

A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH), researchers found. From ...

Bodybuilder Gabriel Ganley died at the age of 22 due to hypertrophic cardiomyopathy (HCM), G1 Globo reported while citing his ...